4 news items
Mizuho Maintains Buy on Adaptimmune Therapeutics, Lowers Price Target to $3
ADAP
17 May 24
Mizuho analyst Graig Suvannavejh maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy and lowers the price target from $9 to $3.
Garry Menzel joins GHO Capital as Operating Partner
ADAP
BDTX
DVA
23 Apr 24
apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
ADAP
AEVA
AIMD
8 Mar 24
announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
ADAP
AFRM
CCL
8 Mar 24
Perform and raised its price target from $45 to $90.
Adaptimmune Therapeutics
- Prev
- 1
- Next